Immunocytochemical characteristics of thyrocytes in radioiodine refractory metastases of papillary thyroid cancer
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-4.13705Keywords:
preoperative prognosis, radioiodine-refractory metastases, thyroglobulin., thyroid papillary carcinoma, thyroid peroxidaseAbstract
Summary. The aim of the work was to carry out an immunocytochemical (ICC) study of thyroid peroxidase (TPO) and thyroglobulin (Tg) expression in the punctates of the radioiodine (RI) refractory and RI uptake metastases of thyroid papillary carcinoma (PTC), on the basis of which it is possible to develop new methods of preoperative prediction of RI resistance and RI therapy efficiency for thyroid papillary carcinoma metastases. Materials and Methods: The ICC research was carried out on a fine needle aspiration biopsy material of 104 metastases that were found after thyroidectomy and RI therapy, i.e. in postoperative period (79 — radioiodine-refractory metastases, 25 — radioiodine-uptake metastases). The ICC analysis of TPO and Tg expression in PTC was performed with the use of monoclonal antibodies against TPO and Tg. Results: RI-refractory (RIRM) and RI-uptake metastases of PTC significantly differ by the percentage of cells expressing TPO and Tg (p < 0.05, and p < 0.05 respectively). The effectiveness of RI therapy was different for patients with different percentages of TPO-positive cells. Conclusion: A statistically significant difference was demonstrated in the expression of TPO in a punctates of RI-resistant and RI-sensitive metastatic TPC, based on which a new method for preoperative prediction of RI resistance and RI therapy efficiency was developed. It was shown that ICC determination of Tg expression in metastases is effective in preoperative monitoring of RI resistance of PTC if the part of Tg-positive cells in punctates is lower than 56%. The comprehensive study of the ICC profile of thyrocytes in RI-uptake metastases punctates allows us to develop a personified approach to prediction, monitoring and therapy of patients with PTC.
References
Bogdanova T, Zurnadzhy L, Nikiforov Y, et al. Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort. Br J Cancer 2015; 113: 1556–64.
Drozd V, Branovan I, Shiglik N, et al. Thyroid cancer induction: nitrates as independent risk factors or risk modulators after radiation exposure, with a focus on the Chernobyl accident. Eur Thyroid J 2018; 7: 67–74.
Markovina S, Grigsby P, Schwarz J, et al. Treatment approach, surveillance, and outcome of well-differentiated thyroid cancer in childhood and adolescence. Thyroid 2014; 24: 1121–6.
Haugen B, Alexander E, Bible K, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodule sand differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1–133.
Pacini F, Yasuhiro I, Markus L. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab 2012; 7: 541–4.
Pfister D, Fagin J. Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol 2008; 26: 4701–4.
Deandreis D, Ghuzlan A, Leboulleux S, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011; 1: 159–69.
Castro M, Bergert E, Goellner J, et al. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 2001; 86: 5627–32.
Min J, Chung J, Lee Y, et al. Relationship between expression of the sodium/iodide symporter and (131)I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001; 28: 639–45.
Mian C, Barollo S, Pennelit G, et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol 2008; 68: 108–16.
Huang M, Batra R, Kogai T, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001; 8: 612–8.
Bätge B, Henning Dralle H, Barbara Padberg B, et al. A histology and immunocytochemistry of differentiated thyroid carcinomas do not predict radioiodine uptake: A clinicomorphological study of 62 recurrent or metastatic tumours. Virchows Archiv 1992; 421: 521–6.
Xin Zhang, Hui Li, Chen Wang. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis. PLoS One 2017; 12: e0179664.
Dralle H, Schwarzrock R, Lang W, et al. Comparison of histology and immunohistochemistry with thyroglobulin serum levels and radioiodine uptake in recurrences and metastases of differentiated thyroid carcinomas. Acta Endocrinol (Copenh) 1985; 108: 504–10.
Bozhok Y‚ Tavokina L, Epstein E. The new things in diagnostic of thyroid cancer. Optimal combination of morphological and immunocytochemistry research methods of punctious materials. Med Announcer 1996; 138: 40–3.
Wiseman S, Griffith O, Deen S, et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 2007; 142: 717–27.
Latrofa F, Ricci D, Montanelli L, et al. Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin. Clin Endocrin Metab 2012; 97: 2380–7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
